1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Israel Pharmaceuticals and Healthcare Report Q4 2015

Israel Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 127 pages

Includes 3 FREE quarterly updates

BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovativedrug sales, with the market boosted by government plans to increase healthcare spending and expandaccess to lifesaving treatments

Headline Expenditure Projections
- Pharmaceuticals: ILS751bn (USD210bn) in 2014 to ILS782bn (USD201bn) in 2015; +42% in localcurrency terms and -44% in US dollar terms Forecast unchanged from Q315
- Healthcare: ILS8067bn (USD2255bn) in 2014 to ILS8580bn (USD2200bn) in 2015; +64% in localcurrency terms and -24% in US dollar terms Forecast unchanged from Q315

Table Of Contents

Israel Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT Analysis 9
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Israel 2011-2019) 16
Healthcare Market Forecast 18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2011-2019) 20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Israel 2011-2019) 23
Patented Drug Market Forecast 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Israel 2011-2019) 26
Generic Drug Market Forecast 27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Israel 2011-2019) 28
OTC Medicine Market Forecast 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Israel 2011-2019) 30
Pharmaceutical Trade Forecast 31
Table: Pharmaceutical Trade Data And Forecasts (Israel 2013-2019) 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Israel 2013-2019) 33
Key Risks To BMI's Forecast Scenario 34
Macroeconomic Forecasts 37
Economic Analysis 37
Expenditure Breakdown 38
Table: Economic Activity (Israel 2010-2019) 42
Industry Risk Reward Indices 43
Middle East and Africa Risk/Reward Index 43
Israel Risk/Reward Index 50
Reward 50
Risk 51
Market Overview 52
Industry Trends And Developments 53
Epidemiology 53
Healthcare Sector 55
Healthcare Insurance 56
Healthcare Coverage Developments 58
Healthcare Financing 59
Healthcare Infrastructure 60
Table: Healthcare Resources (Israel 2009-2014) 61
Table: Healthcare Personnel (Israel 2009-2014) 61
Table: Healthcare Activity (Israel 2009-2014) 62
Research And Development Sector 62
Table: Israel's RandD Legislation - Conditions For OCS Funding 64
Clinical Trials 64
Biotechnology 66
Regulatory Development 69
Regulatory Developments 69
Intellectual Property 70
IP Environment Shortcomings 71
Pricing System 73
Table: Price Build-Up In The Israeli Pharmaceutical Market 74
Reimbursement System 74
Reimbursement Developments 76
Competitive Landscape 78
Pharmaceutical Industry 78
Domestic Pharmaceutical Industry 78
Foreign Pharmaceutical Industry 79
Pharmaceutical Company Developments 79
Pharmaceutical Distribution Sector 80
Pharmaceutical Retail Sector 81
Company Profile 82
Dexcel Pharma 82
GlaxoSmithKline 85
Merck and Co 87
Neopharm Group 89
Novartis 92
Perrigo (Agis Industries) 94
Pfizer 97
Rekah Pharmaceutical Industry 100
Sanofi 102
Taro Pharmaceutical Industries 104
Teva Pharmaceutical Industries 107
Trima 114
Demographic Forecast 116
Table: Population Headline Indicators (Israel 1990-2025) 117
Table: Key Population Ratios (Israel 1990-2025) 118
Table: Urban/Rural Population and Life Expectancy (Israel 1990-2025) 118
Table: Population By Age Group (Israel 1990-2025) 119
Table: Population By Age Group % (Israel 1990-2025) 120
Glossary 121
Methodology 123
Pharmaceutical Expenditure Forecast Model 123
Healthcare Expenditure Forecast Model 123
Notes On Methodology 124
Risk/Reward Index Methodology 125
Index Overview 126
Table: Pharmaceutical Risk/Reward Index Indicators 126
Indicator Weightings 127

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.